Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Showcasing a limited-edition, hand-painted print, the new collection features coordinating styles for kids and adults. By Erin Lassner E-Commerce Writer If you purchase an independently reviewed ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer.

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Atria is a Dividend King with an impressive track record for dividend growth. Eli Lilly has been raising its dividend at a more impressive pace than Altria in recent years. Altria has an ...

Weight loss drugs such as Mounjaro help the body manage blood sugar more effectively, make one feel less hungry, and slow digestion, so the person feels full longer. Mounjaro, chemically known as ...

MNC pharma major Eli Lilly has launched Mounjaro (tirzepatide), a weekly injection for obesity and type 2 diabetes, after obtaining approval from India’s Central Drugs Standard Control ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

American pharmaceutical major Eli Lilly and Company on Thursday (March 20, 2025) launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in ...

April 2 (UPI) --Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly's drug lepodisiran, which inhibits the body's production ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...